Table 10.

Remission rates by two remission definitions in different Disease Activity Score 28 (DAS28) score-based statuses.

	% of Remission (Remission/Nonremission Visits)	Odds Ratio #		% of Remission (Remission/Nonremission Visits)	Odds Ratio #
(A) * The combination of the current study with that published in 2023 (n = 461 visits)
Fulfillment of 2005 modified ARA remission			Fulfillment of 2011 ACR/EULAR remission
DAS28-ESR < 2.6	55.17% (96/78)	Reference	DAS28-ESR < 2.6	64.74% (112/61)	Reference
DAS28-CRP < 2.5	74.53% (79/27)	2.803	DAS28-CRP < 2.5	83.97% (89/17)	3.184
SDAI ≤ 3.3	67.63% (94/45)	1.697	SDAI ≤ 3.3	85.61% (119/20)	3.241
DAS28-MCP-1 < 2.2	71.64% (96/38)	2.053	DAS28-MCP-1 < 2.2	75.37% (101/33)	1.667
(B) & United previous one (n = 835 visits) and (A) (n = 461 visits)
Fulfillment of 2005 modified ARA remission			Fulfillment of 2011 ACR/EULAR remission
DAS28-ESR < 2.6	46.11% (160/187)	Reference	DAS28-ESR < 2.6	56.94% (197/149)	Reference
DAS28-CRP < 2.5	72.73% (128/48)	3.419	DAS28-CRP < 2.5	83.52% (147/29)	4.191
SDAI ≤ 3.3	61.30% (160/101)	1.851	SDAI ≤ 3.3	83.91% (219/42)	3.944
DAS28-MCP-1 < 2.2	73.15% (158/58)	3.184	DAS28-MCP-1 < 2.2	77.78% (168/48)	2.647

* (A) The current study containing mainly DAS28-ESR scores ≤ 3.2 (92% on enrollment) was joined with the study published in 2023 ref. [34] containing all >3.2 (100% on enrollment) to encompass all visits as a group to cover whole ranges of rheumatoid arthritis disease activity in terms of DAS28-ESR scores. All odds ratios ^# vs. the reference in each category gave p < 0.05 in Part (A). Inside parentheses are visit numbers. ^& (B) The data in 2020 ref. [15] were mixed with (A) to calculate data shown in (B). All odds ratios ^# vs. the reference in each category provided p < 0.001 in Part (B). Both DAS28-MCP-1 < 2.2 and DAS28-CRP < 2.5 vs. SDAI ≤ 3.3 for fulfillment of 2005 modified ARA remission offered p = 0.006 and 0.013, respectively.